Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2024 | 3 |
2025 | 2 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial.
Diabetes Obes Metab. 2024 Nov;26(11):5013-5024. doi: 10.1111/dom.15915. Epub 2024 Sep 23.
Diabetes Obes Metab. 2024.
PMID: 39308336
Clinical Trial.
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial.
Gao L, Bian F, Pan T, Jiang H, Feng B, Jiang C, Sun J, Xiao J, Yan P, Ji L.
Gao L, et al.
Diabetes Obes Metab. 2025 Jan;27(1):280-290. doi: 10.1111/dom.16014. Epub 2024 Oct 21.
Diabetes Obes Metab. 2025.
PMID: 39434431
Free PMC article.
Clinical Trial.
Item in Clipboard
A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
He Q, Cheng Z, Li Y, Xing X, Li L, Li X, Zhang J, Xu L, Song W, Li F, Zhang Z, Guo L.
He Q, et al.
Diabetes Obes Metab. 2025 Feb;27(2):965-975. doi: 10.1111/dom.16096. Epub 2024 Dec 4.
Diabetes Obes Metab. 2025.
PMID: 39632416
Clinical Trial.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.